Extended US patent protection for Quantum Genomics’ drug candidates
Quantum Genomics announced that the United States Patent and Trademark Office (USPTO) granted the Company two patents protecting its technology until 2031 and 2033. Quantum Genomics is specializing in cardiovascular diseases with first-in class drug candidates, Brain Aminopeptidase A inhibitors. The Company has also made important progress on its developmentplan. For instance, a Phase IIa trial in heart failure has just been authorized in France. The Company also completed QGC001 Phase IIa trial in hypertension and results are expected in Q3-2016. We slightly increased our target price to €15.37/share to account for the prolonged patent protection of QGC001 in the US, i.e. extended market exclusivity in this major market.
Quantum Gernomics is a biotechnology firm specializing in the development of innovative drugs to combat cardiovascular diseases. Run by professionals in creating and managing technological start-ups and drug development, as well as researchers and inventors, Co. has established contractual relations with institutions of academic excellence in France (Inserm, CollA
First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.